Therefore, drug target data compiled from the DGIdb database27 were mapped to the top immune-negative MHC I-associated genes in given cancer types, to identify potential inhibitors that could enhance tumor response to anti-PD-1 therapy for that cancer type (Fig. 1e). Here, PDCD1 is linked to cancer.